Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2018
Number of items: 1.

2018

Scheid, C., Roellig, C., Weisel, K., Salwender, H-J, Gramatzki, M., Edmaier-Schroeger, K., Sy, O. and Goldschmidt, H. (2018). Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM). Oncol. Res. Treat., 41. S. 189 - 190. BASEL: KARGER. ISSN 2296-5262

This list was generated on Sun Nov 24 05:47:28 2024 CET.